Pediatric Asthma Treatment Market Size, Share and Trends 2024 to 2034

Pediatric Asthma Treatment Market Size and Forecast 2024 to 2034

The global pediatric asthma treatment market size is projected to reach around USD 16.08 billion in 2034 from USD 12.07 billion in 2024, at a CAGR of 2.91% between 2024 and 2034. The worldwide pediatric asthma treatment market is driven by growth in the incidence of asthma and an increase in allergy cases.

Pediatric Asthma Treatment Market Key Takeaways

• North America dominated the pediatric asthma treatment market in 2023.
• Asia Pacific is anticipated to register the fastest growth in the market over the period studied.
• By type, the long-term control medications segment dominated the market in 2023.
• By type, the other segment is expected to show the fastest growth in the market over the forecast period.
• By application, the hospital segment led the market in 2023.
• By application, the clinics segment is expected to grow at the fastest rate in the market during the forecast period.

Market Overview

Pediatric asthma treatment involves a medical approach aimed at managing asthma in children to enhance their quality of life and minimize the risk of complications associated with poorly controlled asthma. Key aspects of managing asthma include promoting physical activity and improving air quality. Symptoms of pediatric asthma include wheezing during breathing, rapid and labored breathing, chest pain, persistent coughing, and fatigue. While pediatric asthma cannot be cured, its prevention is possible through regular monitoring, avoiding smoking around children, managing acid reflux, and addressing other contributing factors.

Pediatric Asthma Treatment Market Growth Factors

• Growth in the presence of different environmental pollutants globally, such as dust and smoke, are driving the growth of the pediatric asthma treatment market.
• The rise in participation of several organizations in spreading awareness of disease control measures is fueling the pediatric asthma treatment market's growth further.
• An increase in the popularity of combination therapies, along with new product launches, is expected to boost the pediatric asthma treatment market growth shortly.

Market Scope

Market Dynamics

Driver

Advancements in research technology

The landscape of the pediatric asthma treatment market is influenced by a range of dynamic factors. Market trends are shaped by advancements in research, technology, and evolving healthcare policies. Variations in patient demographics, such as differences in prevalence rates and geographic Distribution, also affect market behavior.

The competitive environment is further intensified by the introduction of new therapies and emerging market players. Innovation is propelled by collaborations between pharmaceutical companies and research institutions, driving progress in the field. Additionally, changes in regulations and reimbursement policies significantly impact treatment accessibility and affordability and play an important role in shaping market growth.

• In May 2024, Zydus Lifesciences Ltd received final approval from the U.S. health regulator to market its generic Theophylline extended-release tablets used in the treatment of asthma and chronic obstructive pulmonary disease. The approval by the U.S. Food and Drug Administration is for Theophylline extended-release tablets of strengths 300 mg and 450 mg, Zydus Lifesciences said in a regulatory filing.

Restraint

Escalated costs of asthma medications

The high expense associated with asthma medications, especially inhalers, has been a significant barrier to the pediatric asthma treatment market growth in recent years. This cost can restrict access to pediatric asthma treatments, particularly in low- and middle-income countries where many individuals suffer from asthma symptoms. Without sufficient insurance coverage, patients face a substantial financial burden. However, the elevated costs of these medications stem from the complexities of their development and manufacturing processes, as well as the additional expenses related to research, development, clinical trials, and regulatory approvals.

Opportunity

Development of biologics and telehealth

Recent advancements in asthma medications have created lucrative opportunities for key players in the pediatric asthma treatment market. A notable example of such advancements is the development of biologics, which are drugs created from living organisms like bacteria or mice and designed to target specific human molecules. Another emerging trend is the growing adoption of telehealth for remote consultations and asthma management. Furthermore, digital therapeutics, including educational apps and self-management tools, are empowering both children and parents to gain a better understanding of and manage their asthma more effectively.

• In February 2023, EFA launched a digital prize to aid asthma and COPD patients. The European Federation of Allergies and Airways Diseases (EFA) has launched a prize to welcome applications from innovators whose digital products improve the lives and health of asthma and chronic obstructive pulmonary disease (COPD) patients in Europe.

Type Insights

The long-term control medications segment dominated the pediatric asthma treatment market in 2023. The surge in demand for combination inhalers has been a major driver for this segment. Alongside combination inhalers, long-term medication products such as corticosteroids, leukotriene modifiers, and theophylline have also seen increased patient demand. Key drug classes within the long-term control medication segment include a combination of corticosteroids, anticholinergics, immunomodulators, and leukotriene modifiers.

The other segment is expected to show the fastest growth in the pediatric asthma treatment market over the forecast period. The emerging medications with significant growth potential in asthma treatment include biological therapies and combination inhalers. These innovations are aimed at addressing specific asthma phenotypes in children. Biological therapies work by targeting cells or blocking specific molecules that contribute to airway inflammation following exposure to triggers. This exposure activates immune system molecules, leading to swelling in the airways. Hence, this factor can expand segment Growth.

Application Insights

The hospital segment led the pediatric asthma treatment market in 2023. Advanced therapeutics and personalized care improve patient outcomes and accelerate recovery times in hospitals and clinics. When prescribed by trained healthcare professionals, patients are more likely to adhere to treatment protocols and receive accurate, safe administration of essential therapeutics, particularly those delivered via subcutaneous injections. Hence, these factors contribute to more effective control of asthma symptoms.

The clinics segment is expected to grow at the fastest rate in the pediatric asthma treatment market during the forecast period. This can be attributed to the convenience of refilling asthma prescriptions, such as inhaled corticosteroids, at these locations, which significantly contributes to their appeal. Also, the ease of accessing critical asthma medications enhances patient satisfaction and leads clinics to be projected as experiencing the highest rate during the forecast period. Pediatric asthma treatment is not only advancing health outcomes but also driving economic growth across sectors by integrating technology and focusing on patient-centered approaches.

• In January 2024, Manipal Hospital Millers Road opened an Exclusive Asthma and Allergy Clinic in response to the rising incidence of allergies and asthma. The clinic launch was announced on January 13, 2024, during a public forum with a focused group discussion featuring esteemed experts. Manipal Hospital has taken a remarkable initiative by introducing this exclusive clinic for asthma and allergies. The clinic addresses respiratory ailments like dermatitis and allergic rhinitis and allergies.

Regional Insights

North America dominated the pediatric asthma treatment market in 2023. The surge in asthma prevalence and the increase in research and development activities aimed at creating innovative devices are contributing to the growth of the asthma treatment market in countries like the U.S. and Canada. The presence of sophisticated healthcare infrastructure and leading industry players in North America is expected to further drive market expansion in the coming years.

Furthermore, technological advancements in asthma treatment and the growing number of asthma patients in the region are key factors propelling the North American market. Companies such as Johnson & Johnson and Merck are at the forefront, focusing on cutting-edge therapies and digital health solutions.

• In April 2024, the FDA approved the label expansion of AstraZeneca’s Fasenra as an add-on maintenance treatment for severe eosinophilic asthma in patients six to 11 years of age. The FDA greenlit the label expansion of AstraZeneca’s subcutaneous IL-5 receptor blocker Fasnera (bevacizumab), which can now be used as an add-on maintenance treatment for severe eosinophilic asthma in children six to 11 years of age.

Asia Pacific is anticipated to register the fastest growth in the pediatric asthma treatment market over the period studied. The emphasis on respiratory management and improved understanding of pediatric asthma care in countries like India and China are driving significant growth in the Asia Pacific market. Expected to experience rapid expansion in the coming years, the region’s market growth is fueled by an increase in asthma cases, rising disposable incomes, worsening environmental pollution, a growing smoking population, and advancing healthcare infrastructure.

The burgeoning economies and expanding demographics in developing countries such as India and China are likely to boost the pediatric asthma treatment market in Asia Pacific. Additionally, increasing pollution and lifestyle shifts are contributing to this growth. Innovative, cost-effective treatment solutions from emerging market players, along with the extensive access initiatives by major companies like GlaxoSmithKline, are accelerating market development further.

• In June 2022, Glenmark launched a fixed-dose combination drug for asthma patients in India. Asthma is a major non-communicable disease (NCD) affecting both children and adults, caused by inflammation and narrowing of the small airways in the lungs. The company has launched this FDC under the brand name Indamet.

Pediatric Asthma Treatment Market Companies

• AstraZeneca
• Teva Pharmaceutical Industries
• Roche Holding AG/Novartis AG
• Sanofi-Aventis SA
• Mundi-Pharma
• GlaxoSmithKline Plc.
• Merck & Co, Inc.
• Regeneron
• Genentech Inc.
• Mylan N.V.
• Sumitomo Dainippon Pharma Co., Ltd.

Recent Developments

• In January 2023, a new drug combination was launched by Lupin (a multinational pharmaceutical company) to manage and treat asthma among patients. The company launched the product under the brand name DIFIZMA in India comprising a fixed triple dose combination of Indacaterol, Glycopyrronium, and Mometasone.
• In March 2022, Generic Drug Device Combination Product was approved by the United States Food & Drug Administration to treat asthma and obstructive pulmonary disease in patients of 6 years old or older.
• In January 2022, the Food and Drug Administration (U.S.) approved a 40 mg pre-filled needle of Nucala formulated by GSK. The medication is meant for kids aged 6-11 who have extreme eosinophilic asthma.
• In October 2022, the medical device business Acurable, located in the UK, recently revealed that Kibo Ventures, the round's lead investor, had helped the firm raise $10.8 million. The company plans to use the funding to quicken the international growth of the AcuPebble SA100, its first at-home sleep diagnostic gadget that allows users to identify and track obstructive sleep apnea.
• In March 2022, Alkem introduced the Innohaler, a DPI device, to help Asthma and COPD (Chronic Obstructive Pulmonary Disease) patients live more comfortably and to close existing gaps in Asthma care in India. Alkem is entering the core inhalation treatments with the introduction of this device and anticipating that the medication will reach the lungs effectively with each inhalation with increased patient awareness and an adherence program.

Segments Covered in the Report

By Type

• Long-term Control Medications
• Quick-Relief Medications
• Others

By Application

• Hospitals
• Clinics
• Home Care
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa